Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.79Artemis Medicare Services Ltd demonstrates a strong financial profile, marked by exceptional profitability, robust growth, and a very secure debt position. The company is highly effective at converting revenue into profit and is expanding its operations and earnings at an impressive rate. Its reliance on debt is minimal, which significantly lowers long-term financial risk. These strengths suggest a positive future outlook with continued market expansion. However, the analysis also points to areas that present a mixed picture. While day-to-day operational efficiencies like inventory management are strong, the company's effectiveness in generating sales from its large-scale assets, such as buildings and equipment, is less pronounced. Furthermore, direct financial returns to shareholders in the form of dividends are currently low. The company's financial health is fundamentally solid, driven by high profitability and growth, but its value is also tied to how effectively it utilizes its significant investments and balances growth with shareholder returns.
Health Score : 7.79Artemis Medicare Services Ltd demonstrates a strong financial profile, marked by exceptional profitability, robust growth, and a very secure debt position. The company is highly effective at converting revenue into profit and is expanding its operations and earnings at an impressive rate. Its reliance on debt is minimal, which significantly lowers long-term financial risk. These strengths suggest a positive future outlook with continued market expansion. However, the analysis also points to areas that present a mixed picture. While day-to-day operational efficiencies like inventory management are strong, the company's effectiveness in generating sales from its large-scale assets, such as buildings and equipment, is less pronounced. Furthermore, direct financial returns to shareholders in the form of dividends are currently low. The company's financial health is fundamentally solid, driven by high profitability and growth, but its value is also tied to how effectively it utilizes its significant investments and balances growth with shareholder returns.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
50.22
Industry Median
53.17
Small Cap Median
50.07
P/E RATIO
50.07
P/B RATIO
5.56
Industry Median
5.27
Small Cap Median
3.62
P/S RATIO
5.28
Industry Median
3.91
Small Cap Median
2.08
Others
PEG RATIO
0.65
EV/EBITDA RATIO
26.64
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹327.95 as on Sep 1, 2026.
Growth Score : 10.00The company is experiencing an exceptional phase of growth across all key areas. It has demonstrated outstanding expansion in revenue, operating profits, and net income, indicating strong market demand and successful business execution. This robust top-line and bottom-line growth is a significant strength and points to a very positive trajectory. Such comprehensive growth suggests the company is effectively capturing market share and scaling its operations profitably, which is a highly favorable sign for its future prospects.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 36.03 | 32.79 | 19.27 | 6.6 | 15.37 |
| Operating Profit Growth Rate | 94.29 | 38.24 | 41.49 | 14.29 | 23.68 |
| Earnings Per Share (EPS) Growth | 389.8 | 20 | 25.69 | 65.75 | 9.17 |
| Asset Growth Rate | 18.33 | 27.46 | 7.4 | 39.61 | 5.31 |
| Net Income Growth Rate | 416.67 | 22.58 | 28.95 | 67.35 | 26.83 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Indraprastha Medical Corporation Ltd | 8.72 | 17.86 | Neutral | 267.00 | 20.03 | 184.00 |
| 2 | Artemis Medicare Services Ltd | 7.79 | 50.07 | Overvalued | 188.00 | 6.53 | 104.00 |
| 3 | Shalby Ltd | 5.85 | 44.41 | Undervalued | 143.00 | 10.45 | 35.00 |
| 4 | Yatharth Hospital & Trauma Care Services Ltd | 4.89 | 53.56 | Neutral | 292.00 | 9.90 | 170.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤2nd Feb 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
Artemis Medicare Services Ltd. operates a multi-specialty hospital in Gurugram, Haryana. It is a leading healthcare provider in the region, offering a comprehensive range of medical, surgical, and diagnostic services. The company focuses on delivering advanced patient care with state-of-the-art infrastructure.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Artemis Medicare Services Ltd's P/E ratio (TTM) is 50.22, compared to the industry median of 53.17 and large cap median of 50.07.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Artemis Medicare Services Ltd's P/B ratio is 5.56, compared to the industry median of 5.27 and large cap median of 3.62.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Artemis Medicare Services Ltd's P/S ratio is 5.28, compared to the industry median of 3.91 and large cap median of 2.08.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Artemis Medicare Services Ltd's PEG ratio is 0.65.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Artemis Medicare Services Ltd's EV/EBITDA ratio is 26.64.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Artemis Medicare Services Ltd's ROE is 11.12%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Artemis Medicare Services Ltd's ROA is 13.16%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Artemis Medicare Services Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Artemis Medicare Services Ltd's operating margin is 17.39%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Artemis Medicare Services Ltd's net margin is 9.62%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Artemis Medicare Services Ltd's current ratio is 2.22.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Artemis Medicare Services Ltd's debt-to-equity ratio is 0.23.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Artemis Medicare Services Ltd's interest coverage ratio is 5.96.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Artemis Medicare Services Ltd's DPS is ₹0.46.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Artemis Medicare Services Ltd's EPS is 9.17.
(Source line: "Ratios as of 23 Oct 2026, based on last traded price of ₹327.95. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2005
Headquarters: Gurugram, Haryana
Core Offerings: Multi-specialty clinical services, advanced diagnostic services, emergency care, medical tourism, preventive health packages
Stock Listing: NSE (ARTEMISMED), BSE (542919)
Promoter: Artemis Health Sciences Ltd. and associated individuals (including Dr. Devlina Chakravarty)
2005: Incorporated as Artemis Medicare Services Limited. 2007: Established its flagship multi-specialty hospital in Gurugram, Haryana, becoming the first JCI and NABH accredited hospital in Gurugram. Present: Continues to operate its multi-specialty hospital, focusing on high-quality patient care and expanding its service portfolio.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| In-patient Services | N/A | Operating Profit |
| Out-patient Services | N/A | Operating Profit |
| Pharmacy & Diagnostics | N/A | Operating Profit |
In-patient Services: Offers comprehensive care across various medical and surgical specialties requiring hospital admission, including critical care, surgeries, and long-term treatments.
Out-patient Services: Provides consultations, day-care procedures, diagnostic tests, and preventive health check-ups through its specialized clinics and departments.
Pharmacy & Diagnostics: Includes in-house pharmacy services for patients and advanced diagnostic facilities covering radiology, pathology, and laboratory services.
Dr. Devlina Chakravarty (Managing Director & CEO): A highly experienced healthcare professional with over two decades in hospital operations and management. She has been instrumental in the growth and strategic direction of Artemis Hospitals.
Artemis Healthcare Private Limited
Artemis Clinical Research Limited
2021: Bonus Issue (1:1)
The Artemis Medicare Services Ltd share price today is ₹327.95 on NSE (ARTEMISMED), as of 23 Oct 2026.
As of 23 Oct 2026, Artemis Medicare Services Ltd share price is ₹327.95, with previous close ₹327.95. Today's range is ₹327.95 to ₹327.95. The 52-week range is ₹203.35 to ₹378.80.
As of today, Artemis Medicare Services Ltd's market cap is ₹5,709.61 crore (Mid Cap).
Artemis Medicare Services Ltd's current P/E ratio is 50.22, compared to the DIVERSIFIED CONSUMER SERVICES sector average of N/A.
Artemis Medicare Services Ltd's current P/B ratio is 5.56.
Artemis Medicare Services Ltd's current dividend yield is 0.14%. Last dividend of ₹0.50 per share was declared on 15-May-2024.
Artemis Medicare Services Ltd's EPS (TTM) is ₹9.17.
Artemis Medicare Services Ltd. operates a multi-specialty hospital in Gurugram, Haryana. It is a leading healthcare provider in the region, offering a comprehensive range of medical, surgical, and diagnostic services. The company focuses on delivering advanced patient care with state-of-the-art infrastructure.
Artemis Medicare Services Ltd is promoted by Artemis Health Sciences Ltd. and associated individuals (including Dr. Devlina Chakravarty), holding 58.39% as of 23 Oct 2026.
Artemis Medicare Services Ltd is listed on NSE (ARTEMISMED) and BSE (542919). Its next quarterly results are expected on August 2024.
